{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T16:29:38Z","timestamp":1788971378992,"version":"build-2803163510"},"reference-count":47,"publisher":"IMR Press","issue":"2","license":[{"start":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Heart failure with preserved ejection fraction is a very common clinical problem. Its prevalence is increasing with aging of the population. A diverse group of risk factors and etiologies comprise the HFpEF syndrome. No specific therapies have been shown to improve survival for the vast majority of HFpEF cases. Restrictive cardiomyopathies account for a significant portion of HFpEF patients and are characterized by diastolic dysfunction due to infiltration of the myocardium or ventricular hypertrophy. Many of these restrictive diseases occur in the context of myocardial infiltration by other substances such as amyloid, iron or glycogen or endomyocardial fibrosis. These infiltrative diseases usually have important clues in the clinical picture and on cardiac imaging that may allow differentiation from the usual HFpEF phenotype (that is commonly seen in the older, hypertensive patient). Noninvasive diagnosis has replaced endomyocardial biopsy for most instances in the workup of these conditions. Early recognition is important to institute specific therapies and to improve prognosis. In this review, we describe 4 major infiltrative cardiomyopathies (Cardiac Amyloidosis, Sarcoidosis, Hemochromatosis and Fabry disease), and their key imaging features.<\/jats:p>","DOI":"10.31083\/j.rcm.2020.02.65","type":"journal-article","created":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T07:12:31Z","timestamp":1593587551000},"source":"Crossref","is-referenced-by-count":26,"title":["Clinical evaluation of infiltrative cardiomyopathies resulting in heart failure with preserved ejection fraction"],"prefix":"10.31083","volume":"21","author":[{"given":"Nidhi","family":"Madan","sequence":"first","affiliation":[{"name":"Infiltrative Cardiac Disease Program, Division of Cardiology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Kalra","sequence":"first","affiliation":[{"name":"Infiltrative Cardiac Disease Program, Division of Cardiology, Rush University Medical Center, Chicago, IL 60612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Adams, D., Gonzalez-Duarte, A., O'Riordan, W. D., Yang, C. C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., Lin, K. P., Vita, G., Attarian, S., Plant\u00e9-Bordeneuve, V., Mezei, M. M., Campistol, J. M., Buades, J., Brannagan, T. H., 3rd, Kim, B. J., Oh, J., Parman, Y., Sekijima, Y., Hawkins, P. N., Solomon, S. D., Polydefkis, M., Dyck, P. J., Gandhi, P. J., Goyal, S., Chen, J., Strahs, A. L., Nochur, S. V., Sweetser, M. T., Garg, P. P., Vaishnaw, A. K., Gollob, J. A. and Suhr, O. B. (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine 379, 11-21.","DOI":"10.1056\/NEJMoa171615329972753https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29972753"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Banypersad, S. M., Sado, D. M., Flett, A. S., Gibbs, S. D., Pinney, J. H., Maestrini, V., Cox, A. T., Fontana, M., Whelan, C. J., Wechalekar, A. D., Hawkins, P. N. and Moon, J. C. (2013) Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circulation: Cardiovascular Imaging 6, 34-39.","DOI":"10.1161\/CIRCIMAGING.112.978627https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCIMAGING.112.978627"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Barroso, F. A., Judge, D. P., Ebede, B., Li, H., Stewart, M., Amass, L. and Sultan, M. B. (2017) Long-term safety and efficacy of tafamidis for the treatment of hereditary transthyretin amyloid polyneuropathy: results up to 6 years. Amyloid 24, 194-204.","DOI":"10.1080\/13506129.2017.135754528758793https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28758793"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Benson, M. D., Waddington-Cruz, M., Berk, J. L., Polydefkis, M., Dyck, P. J., Wang, A. K., Plante-Bordeneuve, V., Barroso, F. A., Merlini, G., Obici, L., Scheinberg, M., Brannagan, T. H., 3rd, Litchy, W. J., Whelan, C., Drachman, B. M., Adams, D., Heitner, S. B., Conceicao, I., Schmidt, H. H., Vita, G., Campistol, J. M., Gamez, J., Gorevic, P. D., Gane, E., Shah, A. M., Solomon, S. D., Monia, B. P., Hughes, S. G., Kwoh, T. J., McEvoy, B. W., Jung, S. W., Baker, B. F., Ackermann, E. J., Gertz, M. A. and Coelho, T. (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. New England Journal of Medicine 379, 22-31. 29972757https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29972757","DOI":"10.1056\/NEJMoa1716793"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bhatia, R. S., Tu, J. V., Lee, D. S., Austin, P. C., Fang, J., Haouzi, A., Gong, Y. and Liu, P. P. (2006) Outcome of heart failure with preserved ejection fraction in a population-based study. New England Journal of Medicine 355, 260-269. 16855266https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16855266","DOI":"10.1056\/NEJMoa051530"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Birnie, D. H., Nery, P. B., Ha, A. C. and Beanlands, R. S. (2016) Cardiac sarcoidosis. Journal of the American College of Cardiology 68, 411-421. 27443438https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27443438","DOI":"10.1016\/j.jacc.2016.03.605"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Birnie, D. H., Sauer, W. H., Bogun, F., Cooper, J. M., Culver, D. A., Duvernoy, C. S., Judson, M. A., Kron, J., Mehta, D., Cosedis Nielsen, J., Patel, A. R., Ohe, T., Raatikainen, P. and Soejima, K. (2014) HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11, 1305-1323.","DOI":"10.1016\/j.hrthm.2014.03.04324819193https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24819193"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Blankstein, R. and Waller, A. H. (2016) Evaluation of known or suspected cardiac sarcoidosis. Circulation: Cardiovascular Imaging 9, e000867.","DOI":"10.1161\/CIRCIMAGING.113.000867"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Bursi, F., Weston, S. A., Redfield, M. M., Jacobsen, S. J., Pakhomov, S., Nkomo, V. T., Meverden, R. A. and Roger, V. L. (2006) Systolic and diastolic heart failure in the community. JAMA 296, 2209-2216.","DOI":"10.1001\/jama.296.18.220917090767https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17090767"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Buss, S. J., Emami, M., Mereles, D., Korosoglou, G., Kristen, A. V., Voss, A., Schellberg, D., Zugck, C., Galuschky, C., Giannitsis, E., Hegenbart, U., Ho, A. D., Katus, H. A., Schonland, S. O. and Hardt, S. E. (2012) Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers. Journal of the American College of Cardiology 60, 1067-1076.","DOI":"10.1016\/j.jacc.2012.04.0433129a352-52c3-4b02-85a5-630f6231dfb0http:\/\/dx.doi.org\/10.1016\/j.jacc.2012.04.043"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Castano, A., Haq, M., Narotsky, D. L., Goldsmith, J., Weinberg, R. L., Morgenstern, R., Pozniakoff, T., Ruberg, F. L., Miller, E. J., Berk, J. L., Dispenzieri, A., Grogan, M., Johnson, G., Bokhari, S. and Maurer, M. S. (2016) Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis. JAMA Cardiol 1, 880-889.","DOI":"10.1001\/jamacardio.2016.283927557400https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27557400"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., Munisamy, M., Falzone, R., Harrop, J., Cehelsky, J., Bettencourt, B. R., Geissler, M., Butler, J. S., Sehgal, A., Meyers, R. E., Chen, Q., Borland, T., Hutabarat, R. M., Clausen, V. A., Alvarez, R., Fitzgerald, K., Gamba-Vitalo, C., Nochur, S. V., Vaishnaw, A. K., Sah, D. W., Gollob, J. A. and Suhr, O. B. (2013) Safety and efficacy of RNAi therapy for transthyretin amyloidosis. New England Journal of Medicine 369, 819-829.","DOI":"10.1056\/NEJMoa120876023984729https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23984729"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Criado, E., Sanchez, M., Ramirez, J., Arguis, P., de Caralt, T. M., Perea, R. J. and Xaubet, A. (2010) Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics 30, 1567-1586.","DOI":"10.1148\/rg.30610551221071376https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21071376"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Dispenzieri, A., Gertz, M. A., Kumar, S. K., Lacy, M. Q., Kyle, R. A., Saenger, A. K., Grogan, M., Zeldenrust, S. R., Hayman, S. R., Buadi, F., Greipp, P. R., Leung, N., Russell, S. R., Dingli, D., Lust, J. A., Rajkumar, S. V. and Jaffe, A. S. (2014) High sensitivity cardiac troponin T in patients with immunoglobulin light chain amyloidosis. Heart 100, 383-388. 24402772https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24402772","DOI":"10.1136\/heartjnl-2013-304957"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Dispenzieri, A., Gertz, M. A., Saenger, A., Kumar, S. K., Lacy, M. Q., Buadi, F. K., Dingli, D., Leung, N., Zeldenrust, S., Hayman, S. R., Kapoor, P., Grogan, M., Hwa, L., Russell, S. J., Go, R. S., Rajkumar, S. V., Kyle, R. A. and Jaffe, A. (2015) Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T. American Journal of Hematology 90, 524-528.","DOI":"10.1002\/ajh.2400125753178https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25753178"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Dunlay, S. M., Roger, V. L. and Redfield, M. M. (2017) Epidemiology of heart failure with preserved ejection fraction. Nature Reviews: Cardiology 14, 591-602.","DOI":"10.1038\/nrcardio.2017.6528492288https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28492288"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Fine, N. M., Arruda-Olson, A. M., Dispenzieri, A., Zeldenrust, S. R., Gertz, M. A., Kyle, R. A., Swiecicki, P. L., Scott, C. G. and Grogan, M. (2014) Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis. American Journal of Cardiology 113, 1723-1727. 24698461https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24698461","DOI":"10.1016\/j.amjcard.2014.02.030"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Fontana, M., Pica, S., Reant, P., Abdel-Gadir, A., Treibel, T. A., Banypersad, S. M., Maestrini, V., Barcella, W., Rosmini, S., Bulluck, H., Sayed, R. H., Patel, K., Mamhood, S., Bucciarelli-Ducci, C., Whelan, C. J., Herrey, A. S., Lachmann, H. J., Wechalekar, A. D., Manisty, C. H., Schelbert, E. B., Kellman, P., Gillmore, J. D., Hawkins, P. N. and Moon, J. C. (2015) Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 132, 1570-1579.","DOI":"10.1161\/CIRCULATIONAHA.115.01656726362631https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26362631"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Gonzalez-Lopez, E., Lopez-Sainz, A. and Garcia-Pavia, P. (2017) Diagnosis and treatment of transthyretin cardiac amyloidosis. Progress and hope. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition) 70, 991-1004.","DOI":"10.1016\/j.rec.2017.05.036https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1885585717303857"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Gurwitz, J. H., Magid, D. J., Smith, D. H., Goldberg, R. J., McManus, D. D., Allen, L. A., Saczynski, J. S., Thorp, M. L., Hsu, G., Sung, S. H. and Go, A. S. (2013) Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction. American Journal of Medicine 126, 393-400. 23499328https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23499328","DOI":"10.1016\/j.amjmed.2012.10.022"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Hawkins, P. N. (1995) Amyloidosis. Blood Reviews 9, 135-142.","DOI":"10.1016\/s0268-960x(95)90032-27580390https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/7580390"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Iannuzzi, M. C., Rybicki, B. A. and Teirstein, A. S. (2007) Sarcoidosis. New England Journal of Medicine 357, 2153-2165.","DOI":"10.1056\/NEJMra07171418032765https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18032765"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Karamitsos, T. D., Piechnik, S. K., Banypersad, S. M., Fontana, M., Ntusi, N. B., Ferreira, V. M., Whelan, C. J., Myerson, S. G., Robson, M. D., Hawkins, P. N., Neubauer, S. and Moon, J. C. (2013) Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC: Cardiovascular Imaging 6, 488-497.","DOI":"10.1016\/j.jcmg.2012.11.01323498672https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23498672"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Kouranos, V., Tzelepis, G. E., Rapti, A., Mavrogeni, S., Aggeli, K., Douskou, M., Prasad, S., Koulouris, N., Sfikakis, P., Wells, A. and Gialafos, E. (2017) Complementary role of CMR to conventional screening in the diagnosis and prognosis of cardiac sarcoidosis. JACC: Cardiovascular Imaging 10, 1437-1447.","DOI":"10.1016\/j.jcmg.2016.11.01928330653https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28330653"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kristen, A. V., Giannitsis, E., Lehrke, S., Hegenbart, U., Konstandin, M., Lindenmaier, D., Merkle, C., Hardt, S., Schnabel, P. A., R\u00f6cken, C., Schonland, S. O., Ho, A. D., Dengler, T. J. and Katus, H. A. (2010) Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 116, 2455-2461. 20581312https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20581312","DOI":"10.1182\/blood-2010-02-267708"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Kubo, T., Gimeno, J. R., Bahl, A., Steffensen, U., Steffensen, M., Osman, E., Thaman, R., Mogensen, J., Elliott, P. M., Doi, Y. and McKenna, W. J. (2007) Prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy with restrictive phenotype. Journal of the American College of Cardiology 49, 2419-2426.","DOI":"10.1016\/j.jacc.2007.02.06117599605https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17599605"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Kyle, R. A., Linos, A., Beard, C. M., Linke, R. P., Gertz, M. A., O'Fallon, W. M. and Kurland, L. T. (1992) Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 79, 1817-1822. 1558973https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1558973","DOI":"10.1182\/blood.V79.7.1817.bloodjournal7971817"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Maurer, M. S., Hanna, M., Grogan, M., Dispenzieri, A., Witteles, R., Drachman, B., Judge, D. P., Lenihan, D. J., Gottlieb, S. S., Shah, S. J., Steidley, D. E., Ventura, H., Murali, S., Silver, M. A., Jacoby, D., Fedson, S., Hummel, S. L., Kristen, A. V., Damy, T., Plante-Bordeneuve, V., Coelho, T., Mundayat, R., Suhr, O. B., Waddington Cruz, M. and Rapezzi, C. (2016) Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey). Journal of the American College of Cardiology 68, 161-172.","DOI":"10.1016\/j.jacc.2016.03.59627386769https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27386769"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Maurer, M. S., Schwartz, J. H., Gundapaneni, B., Elliott, P. M., Merlini, G., Waddington-Cruz, M., Kristen, A. V., Grogan, M., Witteles, R., Damy, T., Drachman, B. M., Shah, S. J., Hanna, M., Judge, D. P., Barsdorf, A. I., Huber, P., Patterson, T. A., Riley, S., Schumacher, J., Stewart, M., Sultan, M. B. and Rapezzi, C. (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. New England Journal of Medicine 379, 1007-1016.","DOI":"10.1056\/NEJMoa180568930145929https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30145929"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"McCafferty, E. H. and Scott, L. J. (2019) Migalastat: A review in Fabry disease. Drugs 79, 543-554.","DOI":"10.1007\/s40265-019-01090-430875019https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30875019"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Mohty, D., Damy, T., Cosnay, P., Echahidi, N., Casset-Senon, D., Virot, P. and Jaccard, A. (2013) Cardiac amyloidosis: updates in diagnosis and management. Archives of Cardiovascular Diseases 106, 528-540.","DOI":"10.1016\/j.acvd.2013.06.05133fe0d18-a1b8-4909-af7d-92222c5a91eehttp:\/\/dx.doi.org\/10.1016\/j.acvd.2013.06.051"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Mollee, P., Renaut, P., Gottlieb, D. and Goodman, H. (2014) How to diagnose amyloidosis. Internal Medicine Journal 44, 7-17. 24024789https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24024789","DOI":"10.1111\/imj.12288"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Muchtar, E., Blauwet, L. A. and Gertz, M. A. (2017) Restrictive cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circulation Research 121, 819-837.","DOI":"10.1161\/CIRCRESAHA.117.31098228912185https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28912185"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Muchtar, E., Buadi, F. K., Dispenzieri, A. and Gertz, M. A. (2016) Immunoglobulin light-chain amyloidosis: from basics to new developments in diagnosis, prognosis and therapy. Acta Haematologica 135, 172-190.","DOI":"10.1159\/00044320026771835https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26771835"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Mundigler, G., Gaggl, M., Heinze, G., Graf, S., Zehetgruber, M., Lajic, N., Voigtlander, T., Mannhalter, C., Sunder-Plassmann, R., Paschke, E., Fauler, G. and Sunder-Plassmann, G. (2011) The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. European Journal of Echocardiography 12, 744-749.","DOI":"10.1093\/ejechocard\/jer112073bdc4a-fb36-48b9-a00d-93ae3760165ehttp:\/\/dx.doi.org\/10.1093\/ejechocard\/jer112"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Nordin, S., Kozor, R., Bulluck, H., Castelletti, S., Rosmini, S., Abdel-Gadir, A., Baig, S., Mehta, A., Hughes, D., and Moon, J. C. (2016) Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. Journal of the American College of Cardiology 68, 1707-1708. 27712787https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27712787","DOI":"10.1016\/j.jacc.2016.07.741"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Owan, T. E., Hodge, D. O., Herges, R. M., Jacobsen, S. J., Roger, V. L. and Redfield, M. M. (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. New England Journal of Medicine 355, 251-259.","DOI":"10.1056\/NEJMoa05225616855265https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16855265"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Pereira, N. L., Grogan, M. and Dec, G. W. (2018) Spectrum of restrictive and infiltrative cardiomyopathies: part 1 of a 2-part series. Journal of the American College of Cardiology 71, 1130-1148.","DOI":"10.1016\/j.jacc.2018.01.01629519355https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29519355"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Perez de Isla, L., Canadas, V., Contreras, L., Almeria, C., Rodrigo, J. L., Aubele, A. L., Mataix, L., Herrera, D., Serra, V. and Zamorano, J. (2009) Diastolic heart failure in the elderly: in-hospital and long-term outcome after the first episode. International Journal of Cardiology 134, 265-270.","DOI":"10.1016\/j.ijcard.2007.12.05918353469https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18353469"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Phelan, D., Collier, P., Thavendiranathan, P., Popovic, Z. B., Hanna, M., Plana, J. C., Marwick, T. H. and Thomas, J. D. (2012) Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart 98, 1442-1448. 22865865https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22865865","DOI":"10.1136\/heartjnl-2012-302353"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Rivenes, S. M., Kearney, D. L., Smith, E. O., Towbin, J. A. and Denfield, S. W. (2000) Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 102, 876-882. 10952956https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10952956","DOI":"10.1161\/01.CIR.102.8.876"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Selvanayagam, J. B., Hawkins, P. N., Paul, B., Myerson, S. G. and Neubauer, S. (2007) Evaluation and management of the cardiac amyloidosis. Journal of the American College of Cardiology 50, 2101-2110.","DOI":"10.1016\/j.jacc.2007.08.02869fdc95e-d437-486f-b240-31081702883bhttp:\/\/www.sciencedirect.com\/science\/article\/pii\/S0735109707028811"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Solomon, S. D., Adams, D., Kristen, A., Grogan, M., Gonzalez-Duarte, A., Maurer, M. S., Merlini, G., Damy, T., Slama, M. S., Brannagan, T. H., 3rd, Dispenzieri, A., Berk, J. L., Shah, A. M., Garg, P., Vaishnaw, A., Karsten, V., Chen, J., Gollob, J., Vest, J. and Suhr, O. (2019) Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 139, 431-443.","DOI":"10.1161\/CIRCULATIONAHA.118.03583130586695https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30586695"},{"key":"ref44","unstructured":"Srimahachota, S., Rojnuckarin, P., Udayachalerm, W., Buddhari, W., Chaipromprasit, J., Lertsuwunseri, V., Akkawat, B. and Jirapattrathamrong, S. (2013) Comparison of original and generic clopidogrel 600 mg loading dose in the patients who planned undergoing coronary angiography. Journal of the Medical Association of Thailand 95, 1495-1500. 23390778https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23390778"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Uemura, A., Morimoto, S., Kato, Y., Hiramitsu, S., Ohtsuki, M., Kato, S., Sugiura, A., Miyagishima, K., Iwase, M. and Hishida, H. (2005) Relationship between basal thinning of the interventricular septum and atrioventricular block in patients with cardiac sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases 22, 63-65.","DOI":"10.1007\/s11083-005-9006-915881282https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15881282"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Yang, L., Krefting, I., Gorovets, A., Marzella, L., Kaiser, J., Boucher, R. and Rieves, D. (2012) Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 265, 248-253.","DOI":"10.1148\/radiol.12112783fddcee79-df97-4de1-81ef-af7c43ae4621http:\/\/dx.doi.org\/10.1148\/radiol.12112783"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Youssef, G., Leung, E., Mylonas, I., Nery, P., Williams, K., Wisenberg, G., Gulenchyn, K. Y., Dekemp, R. A., Dasilva, J., Birnie, D., Wells, G. A. and Beanlands, R. S. (2012) The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. Journal of Nuclear Medicine 53, 241-248.","DOI":"10.2967\/jnumed.111.09066217193ab2-f310-4c5f-bfed-ca4d39a08c50http:\/\/dx.doi.org\/10.2967\/jnumed.111.090662"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/21\/2\/10.31083\/j.rcm.2020.02.65","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T16:54:48Z","timestamp":1732726488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/21\/2\/10.31083\/j.rcm.2020.02.65"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020]]}},"alternative-id":["2153-8174-21-2-181"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm.2020.02.65","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]},"article-number":"181"}}